Company Focus
CSL Limited.
Latest CSL Limited. News
Biotechnology
Japanese drugmaker Takeda said its investigational immunoglobulin therapy TAK-881 met the primary endpoint in a pivotal Phase II/III study in patients with primary immunodeficiency disease, strengthening the company’s position in a steadily growing plasma therapies market. 6 May 2026
Related News
Insights
Company Spotlight
A specialty pharmaceutical company engaged in the discovery, development, manufacturing and marketing of branded prescription and nonprescription products in more than 60 countries on five continents.
Latest News & Features of interest to CSL Limited.
Biotechnology
Servier Ventures, the VC fund created by the French drugmaker, has selected Cytospire Therapeutics for its first investment. 13 May 2026
Pharmaceutical
Hengrui Pharma's Hong Kong-listed shares surged significantly to around HK$76.00 - up over 13% - after the company announced a massive licensing accord with Bristol-Myers Squibb. 12 May 2026
Pharmaceutical
Germany’s Bayer has reported a solid start to 2026, with first-quarter earnings beating analyst expectations, driven primarily by strong performance in its Crop Science division. 12 May 2026
Pharmaceutical
UK pharma major GSK has entered into an exclusive strategic collaboration with Sino Biopharmaceutical (SBP Group), through its subsidiary Chia Tai Tianqing (CTTQ), to accelerate bepirovirsen in mainland China at launch. 12 May 2026
Biotechnology
AOP Health, an Austrian enterprise group focused on integrated therapies for rare diseases and critical care, today announced a strategic partnership with VRG Therapeutics, an AI-driven developer for miniproteins based in Budapest, Hungary. 12 May 2026
Pharmaceutical
US drug developer Cytokinetics today announced the closing of an underwritten public offering of 11,338,028 shares of its common stock. 11 May 2026
Pharmaceutical
This weekend at the European Society of Cardiology’s Heart Failure 2026 Congress in Barcelona), the first data from AstraZeneca’s Phase III CARDIO-TTRansform trial was presented. 11 May 2026
Biotechnology
CSL Ltd shares are being hammered after the Australian biotech released another painful update to the market, with the stock closing down 16% at A$100.75, having fallen as much as 20%. 11 May 2026
Pharmaceutical
Among important regulatory news last week, the US Food and Drug Administration (FDA) approved Axsome Therapeutics’ Alzheimer’s agitation candidate Auvelity, and an FDA Advisory Committee voted against approval of AstraZeneca’s breast cancer drug camizestrant. US biotech Madrigal Pharma revealed a deal with Arrowhead Pharma to acquire rights to its investigational MASH treatment ARO-PNPLA3. Germany’s Bayer announced its proposed acquisition of Perfuse Therapeutic, aiming to reinforce it ophthalmics drug pipeline. 10 May 2026
Biotechnology
US biotech major Gilead Sciences has reported first-quarter 2026 results ahead of Wall Street expectations, driven by continued strength in its HIV franchise. 8 May 2026
Latest In Brief for CSL Limited.
Pharmaceutical
KDventures has revealed that the planned reversed acquisition of the portfolio company SVF Vaccines by Novakand Pharma will not be completed, following Nasdaq’s rejection of an application for continued listing of the combined entity. 25 February 2026
Copyright © The Pharma Letter 2026
| Headless Content Management with Blaze